What is Enlicitide?
Enlicitide is a ring-shaped peptide designed to block PCSK9, the same target as the antibody medicines Repatha and Praluent, but taken as a daily pill instead of an injection. The FDA approved it in July 2026 under the brand name Lipfendra to lower LDL cholesterol in adults with high cholesterol.
Biological role or research focus
LDL cholesterol lowering with a PCSK9-blocking pill.
The trial measured cholesterol levels, not heart attacks, strokes or deaths. Whether enlicitide lowers those events, as the injected PCSK9 antibodies have been shown to, is being tested in a separate outcomes trial that had not reported when this page was checked.
Role reference: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide · 2026 ↗
Names you may encounter
Enlicitide decanoate · MK-0616 · Lipfendra
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Oral macrocyclic (ring-shaped) peptide that blocks PCSK9; approved by the FDA in July 2026 as Lipfendra
- Research focus
- LDL cholesterol lowering with a PCSK9-blocking pill
- Featured evidence
- Human randomized phase 3 trial
- Source check
- October 6, 2026
Source: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide · 2026 ↗
Quick answers
- Is Enlicitide FDA approved?
- Yes. Lipfendra tablets (NDA 220848, approved July 15, 2026), an oral PCSK9 inhibitor to lower LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. Source ↗
- Is Enlicitide safe?
- Enlicitide (Lipfendra) is a newly approved oral PCSK9 inhibitor; in year-long trials, side effects were similar to placebo overall, with more diarrhea and dizziness in one study. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Enlicitide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| CORALreef Lipids: enlicitide versus placebo for 52 weeks (2026) | Human randomized phase 3 trial | 2,909 adults who had already had a major atherosclerotic event, or were at risk of a first one, with LDL cholesterol above set thresholds despite their usual treatment. Mean age 63; 39% women. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized phase 3 trial · 2026
CORALreef Lipids: enlicitide versus placebo for 52 weeks
What did this publication test, and what did it find?
- Population / model
- 2,909 adults who had already had a major atherosclerotic event, or were at risk of a first one, with LDL cholesterol above set thresholds despite their usual treatment. Mean age 63; 39% women.
- Study design
- Multinational, double-blind, placebo-controlled trial. Participants were randomly assigned two to one to enlicitide or placebo for 52 weeks. The main outcome was the percent change in LDL cholesterol at week 24.
- Main finding
- LDL cholesterol fell by about 57% with enlicitide and rose by 3% with placebo at week 24, a difference of about 56 percentage points. Reductions held at week 52, and non-HDL cholesterol, apolipoprotein B and lipoprotein(a) also fell more than with placebo. An earlier phase 2b trial reported reductions of up to about 61% after eight weeks.
- Limits & context
- The trial measured cholesterol levels, not heart attacks, strokes or deaths. Whether enlicitide lowers those events, as the injected PCSK9 antibodies have been shown to, is being tested in a separate outcomes trial that had not reported when this page was checked.
Source: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide · 2026 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
34 registered studies name Enlicitide as an intervention; 7 are recruiting or under way, 0 have not started recruiting yet and 27 completed. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 34 listed studies.
Search additional PubMed records ↗Risks & interactions
Enlicitide (Lipfendra) is a newly approved oral PCSK9 inhibitor; in year-long trials, side effects were similar to placebo overall, with more diarrhea and dizziness in one study.
The July 2026 FDA label rests on two year-long placebo-controlled trials in about 3,200 adults and lists no contraindications and no warnings and precautions section. Long-term safety, rare side effects and effects on heart attacks and strokes are not yet known.
Take extra care with: Pregnancy or breastfeeding
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Serious risks
- Possible harm to an unborn baby, based on how the drug works (human data are lacking)
Common side effects
- diarrhea
- dizziness
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Lipfendra (enlicitide) prescribing information, July 2026 ↗ · Drugs@FDA: Lipfendra, NDA 220848 ↗ · Navar et al., NEJM 2026: CORALreef Lipids trial of enlicitide ↗
Safety & what remains unknown
Adverse events did not appear to differ between enlicitide and placebo over 52 weeks. Longer-term safety and rare effects will come from the ongoing outcomes trial and post-approval monitoring; the prescribing information is the reference for precautions.
Source: FDA · Lipfendra prescribing information · July 2026 ↗
Evidence boundaries
The trial measured cholesterol levels, not heart attacks, strokes or deaths. Whether enlicitide lowers those events, as the injected PCSK9 antibodies have been shown to, is being tested in a separate outcomes trial that had not reported when this page was checked.
Source: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide · 2026 ↗
Regulatory status
- U.S. FDA approval
- Approved
Lipfendra tablets (NDA 220848, approved July 15, 2026), an oral PCSK9 inhibitor to lower LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
Enlicitide is a prescription medicine for lowering LDL cholesterol, used alongside diet and usually other cholesterol treatment. Its approval is based on LDL lowering; a large outcomes trial is still testing whether it reduces heart attacks and strokes. It is not a research peptide, and PepsRadar does not link to sellers from this page. For how it compares with the antibody and gene-silencing PCSK9 medicines, see the PCSK9 guide linked below.
Source: FDA · Lipfendra prescribing information · July 2026 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
Biology & proposed mechanism
PCSK9 is a protein that marks the liver's LDL receptors for destruction. With fewer receptors, less LDL cholesterol is cleared from the blood. Enlicitide binds PCSK9 and stops it attaching to those receptors, so more of them keep recycling and LDL levels fall. Most peptides are broken down in the gut; enlicitide's ring structure and its formulation were engineered so enough is absorbed when swallowed.
Source: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide · 2026 ↗
Questions worth asking
- Is enlicitide the same kind of drug as Repatha?
- What material, population, and route were actually studied?
- The trial measured cholesterol levels, not heart attacks, strokes or deaths. Whether enlicitide lowers those events, as the injected PCSK9 antibodies have been shown to, is being tested in a separate outcomes trial that had not reported when this page was checked.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is enlicitide the same kind of drug as Repatha?
They block the same target, PCSK9, but they are very different molecules. Repatha is a large antibody given by injection; enlicitide is a much smaller ring-shaped peptide taken as a pill. Repatha has outcomes-trial evidence of fewer heart attacks and strokes; enlicitide's outcomes trial was still under way when this page was checked.
Source: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide · 2026 ↗
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
Source: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide · 2026 ↗
References & editorial record
Source notes checked 2026-10-06. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
Antibody, peptide or gene silencer: three ways to block PCSK9 and lower LDL
Repatha, Praluent, Leqvio and the new pill enlicitide all lower LDL cholesterol by targeting the same protein, PCSK9. They are very different kinds of molecules, and only some have been shown to prevent heart attacks and strokes.
Read the guide →
